What bremelanotide is
Bremelanotide is a synthetic cyclic heptapeptide. It is an analog of alpha-melanocyte-stimulating hormone (alpha-MSH), modified into a stable ring structure that resists enzymatic breakdown [1]. In the research and early-development literature it is referred to as PT-141; in regulatory and clinical use, it is called by its International Nonproprietary Name, bremelanotide. Both names describe the same molecule.
Unlike treatments for sexual dysfunction that act on blood flow, bremelanotide acts in the brain. It is an agonist at the melanocortin receptor family, with therapeutically relevant activity at MC4R in the hypothalamus [5]. That central mechanism is what distinguishes it from older approaches and is the focus of most of the published clinical research.
This site is an editorial summary of that research record — what bremelanotide has been studied for, what the Phase 3 trials showed, who the prescribing clinicians are, and what the FDA-approved labeling actually says. It is not a clinic, and it does not sell any product.
What it is approved to treat
The U.S. Food and Drug Administration approved bremelanotide on June 21, 2019 for one indication: the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [9]. Each word of that indication carries weight.
Premenopausal — the approval is restricted to women in their reproductive years. The drug is not indicated for HSDD in postmenopausal women, and it is not indicated for any condition in men [9].
Acquired — the low desire developed after a period of normal sexual function, rather than being lifelong. Generalized — the low desire is present across situations and partners, not limited to a specific context or relationship.
Hypoactive sexual desire disorder — a clinical diagnosis defined by persistently low sexual desire that causes meaningful distress and is not better explained by another medical condition, a psychiatric condition, a medication side effect, or a relationship problem [13]. The diagnosis is made by a clinician who has taken a full history and ruled out those other causes.
The drug is marketed in the United States as the FDA-approved brand under a single label. International approval is limited; bremelanotide is not broadly registered in other major markets as of this writing.
What the science suggests
Bremelanotide does not increase blood flow to genital tissues the way a phosphodiesterase-5 inhibitor does. It works centrally, in the brain.
Its proposed mechanism is agonism at melanocortin-4 receptors (MC4R) concentrated in the medial preoptic area of the hypothalamus and adjacent limbic regions [5]. MC4R activation in these circuits is hypothesized to drive downstream dopamine release in the pathways that regulate sexual desire. The FDA label lists the binding-affinity order as MC1R > MC4R > MC3R > MC5R > MC2R [9], though the therapeutically relevant receptor for the sexual-desire effect is understood to be MC4R.
The central mechanism explains both the therapeutic effect and several of the drug's tolerability features. Nausea and flushing — the two most common side effects — are consistent with melanocortin-receptor activation. Focal hyperpigmentation, reported in roughly 1% of patients in the Phase 3 trials, is thought to be mediated by off-target MC1R activation on skin melanocytes [11].
What the trials showed
The pivotal evidence comes from two identically designed Phase 3 trials known as RECONNECT (studies 301 and 302), enrolling a combined 1,267 randomized premenopausal women with acquired, generalized HSDD [1]. Both trials met their co-primary endpoints: improvement in the Female Sexual Function Index — Desire domain (FSFI-D) and reduction in distress about low desire as measured by Item 13 of the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSDS-DAO Item 13).
The effect sizes are statistically significant but clinically modest. The FSFI-D improvement over placebo was 0.30 in study 301 and 0.42 in study 302 (both p<0.001) [1]. In a published responder analysis, approximately 58% of women on bremelanotide met responder criteria on FSFI-D, compared with approximately 35% on placebo [14].
A 52-week open-label extension study followed RECONNECT participants who chose to continue. Improvements in desire and distress scores were sustained over a year of as-needed use, and no new safety signals emerged [2].
The 2025 recommendations from the 5th International Consultation on Sexual Medicine (ICSM) endorsed bremelanotide as an as-needed pharmacologic option for premenopausal women with HSDD, with moderate evidence support, alongside other available treatments and psychological interventions [13].
Who studies and prescribes it
Because the FDA-approved indication is a specific clinical diagnosis in women, the clinicians who most often evaluate and prescribe bremelanotide are obstetrician-gynecologists, primary care physicians who manage women's health, and sexual medicine specialists with advanced training in female sexual dysfunction. Many of the published expert authors are affiliated with the International Society for the Study of Women's Sexual Health (ISSWSH).
The FAQ page covers the question of which kind of doctor in more depth, including what the clinical evaluation actually involves and what to expect at a first visit. For the science behind the drug — the mechanism, the trial data, the safety record — start with the research page.